Home > Publications Database > Drug screen in iPSC-Neurons identifies nucleoside analogs as inhibitors of (G4C2)n expression in C9orf72 ALS/FTD > print

001     164645
005     20230915090554.0
024 7 _ |a 10.1016/j.celrep.2022.110913
|2 doi
024 7 _ |a 2211-1247
|2 ISSN
024 7 _ |a 2639-1856
|2 ISSN
024 7 _ |a altmetric:129388830
|2 altmetric
024 7 _ |a pmid:35675776
|2 pmid
037 _ _ |a DZNE-2022-01175
082 _ _ |a 610
100 1 _ |a Czuppa, Mareike
|0 P:(DE-2719)2811917
|b 0
|e First author
|u dzne
245 _ _ |a Drug screen in iPSC-Neurons identifies nucleoside analogs as inhibitors of (G4C2)n expression in C9orf72 ALS/FTD
260 _ _ |a [New York, NY]
|c 2022
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660120456_6915
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a (CC BY-NC-ND)
520 _ _ |a An intronic (G4C2)n expansion in C9orf72 causes amyotrophic lateral sclerosis and frontotemporal dementia primarily through gain-of-function mechanisms: the accumulation of sense and antisense repeat RNA foci and dipeptide repeat (DPR) proteins (poly-GA/GP/GR/PA/PR) translated from repeat RNA. To therapeutically block this pathway, we screen a library of 1,430 approved drugs and known bioactive compounds in patient-derived induced pluripotent stem cell-derived neurons (iPSC-Neurons) for inhibitors of DPR expression. The clinically used guanosine/cytidine analogs decitabine, entecavir, and nelarabine reduce poly-GA/GP expression, with decitabine being the most potent. Hit compounds nearly abolish sense and antisense RNA foci and reduce expression of the repeat-containing nascent C9orf72 RNA transcript and its mature mRNA with minimal effects on global gene expression, suggesting that they specifically act on repeat transcription. Importantly, decitabine treatment reduces (G4C2)n foci and DPRs in C9orf72 BAC transgenic mice. Our findings suggest that nucleoside analogs are a promising compound class for therapeutic development in C9orf72 repeat-expansion-associated disorders.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 2 |a Amyotrophic Lateral Sclerosis: drug therapy
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: genetics
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: metabolism
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a C9orf72 Protein: genetics
|2 MeSH
650 _ 2 |a C9orf72 Protein: metabolism
|2 MeSH
650 _ 2 |a DNA Repeat Expansion
|2 MeSH
650 _ 2 |a Decitabine: metabolism
|2 MeSH
650 _ 2 |a Dipeptides: metabolism
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: genetics
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Induced Pluripotent Stem Cells: metabolism
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Neurons: metabolism
|2 MeSH
650 _ 2 |a Nucleosides: metabolism
|2 MeSH
650 _ 2 |a RNA, Antisense: metabolism
|2 MeSH
700 1 _ |a Dhingra, Ashutosh
|0 P:(DE-2719)2811729
|b 1
|u dzne
700 1 _ |a Zhou, Qihui
|0 P:(DE-2719)2811347
|b 2
|u dzne
700 1 _ |a Schludi, Carina
|0 P:(DE-2719)9001337
|b 3
|u dzne
700 1 _ |a Koenig, Laura
|0 P:(DE-2719)9001381
|b 4
|u dzne
700 1 _ |a Scharf, Elisabeth
|0 P:(DE-2719)9001326
|b 5
|u dzne
700 1 _ |a Farny, Daniel
|0 P:(DE-2719)2812127
|b 6
|u dzne
700 1 _ |a Dalmia, Anupriya
|0 P:(DE-2719)2812478
|b 7
|u dzne
700 1 _ |a Täger, Joachim
|0 P:(DE-2719)2811804
|b 8
|u dzne
700 1 _ |a Castillo Lizardo, Melissa Gissel
|0 P:(DE-2719)2810917
|b 9
|u dzne
700 1 _ |a Katona, Eszter
|0 P:(DE-2719)9001378
|b 10
|u dzne
700 1 _ |a Mori, Kohji
|b 11
700 1 _ |a Aumer, Tina
|b 12
700 1 _ |a Schelter, Florian
|b 13
700 1 _ |a Müller, Markus
|b 14
700 1 _ |a Carell, Thomas
|b 15
700 1 _ |a Kalliokoski, Tuomo
|0 0000-0001-8037-2434
|b 16
700 1 _ |a Messinger, Josef
|b 17
700 1 _ |a Rizzu, Patrizia
|0 P:(DE-2719)2810718
|b 18
|u dzne
700 1 _ |a Heutink, Peter
|0 P:(DE-2719)2810728
|b 19
|u dzne
700 1 _ |a Edbauer, Dieter
|0 P:(DE-2719)2231621
|b 20
|e Last author
|u dzne
773 _ _ |a 10.1016/j.celrep.2022.110913
|g Vol. 39, no. 10, p. 110913 -
|0 PERI:(DE-600)2649101-1
|n 10
|p 110913
|t Cell reports
|v 39
|y 2022
|x 2211-1247
856 4 _ |u https://pub.dzne.de/record/164645/files/DZNE-2022-01175.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/164645/files/DZNE-2022-01175.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:164645
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2811917
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2811729
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811347
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001337
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9001381
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2812127
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812478
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2811804
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2810917
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9001378
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2810718
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2810728
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2231621
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 1
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-03
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-03
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)
|0 LIC:(DE-HGF)CCBYNCNDNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-03
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL REP : 2021
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-01-26T13:08:57Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-01-26T13:08:57Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-01-26T13:08:57Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-17
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELL REP : 2021
|d 2022-11-17
920 1 _ |0 I:(DE-2719)1110004
|k AG Edbauer
|l Cell Biology of Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1210002
|k AG Heutink 1
|l Genome Biology of Neurodegenerative Diseases
|x 1
920 1 _ |0 I:(DE-2719)6000016
|k München common
|l München common
|x 2
920 1 _ |0 I:(DE-2719)1210009
|k AG Rizzu
|l Applied Genomics of Neurodegenerative Diseases
|x 3
920 1 _ |0 I:(DE-2719)5000080
|k AG Zhou
|l Adaptive Immunity in Neurodegeneration
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1110004
980 _ _ |a I:(DE-2719)1210002
980 _ _ |a I:(DE-2719)6000016
980 _ _ |a I:(DE-2719)1210009
980 _ _ |a I:(DE-2719)5000080
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21